# HIMALAYA (NCT03298451)

> Study of Durvalumab and Tremelimumab as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma

No report yet. It can be ordered.

- Drugs tested: tremelimumab plus durvalumab; durvalumab
- Indication: first-line unresectable hepatocellular carcinoma

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03298451
- Phase: PHASE3
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: AstraZeneca
- Conditions: Hepatocellular Carcinoma
- Interventions: Durvalumab; Tremelimumab (Regimen 1); Tremelimumab (Regimen 2); Sorafenib; Durvalumab (Regimen 1); Durvalumab (Regimen 2)
- Enrollment: 1324
- Primary outcome: Overall Survival (OS) - Treme 300 mg x1 Dose + Durva 1500 mg vs Sora 400 mg

## Indexed commentary on HIMALAYA so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 2
- YouTube: 1

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=himalaya-nct03298451